{"title":"长效硝苯地平治疗原发性高血压:心脏病专家综述。","authors":"Prakash Kumar Hazra, Ashwani Mehta, Bhupen Desai, Umeshwar Pandey, Kapil Dev Mehta, Sarita Bajpai, Deepak Prasad","doi":"10.62347/RPMZ6407","DOIUrl":null,"url":null,"abstract":"<p><p>Calcium channel antagonists, specifically long-acting nifedipine formulations, play a crucial role in treating hypertension and angina. Originally used for angina, nifedipine has been widely employed as an antihypertensive medication for over 40 years. It offers rapid action and oral bioavailability with minimal maternal or fetal side effects, making it suitable for treating hypertensive crises during pregnancy. However, it can cause a sudden drop in blood pressure and tachycardia. Long-acting formulations, such as gastrointestinal therapeutic systems, gradually release nifedipine over 24 hours, mitigating these issues. This review aims to assess the clinical efficacy and safety of long-acting nifedipine formulations in managing essential hypertension, with a focus on improving blood pressure control and addressing challenges in uncontrolled and resistant hypertension. Furthermore, long-acting nifedipine provides therapeutic advantages beyond hypertension management, showing efficacy in treating comorbid conditions such as chronic kidney disease and diabetes. Global studies support its efficacy, suggesting that a shift toward the use of long-acting nifedipine can help address the global hypertension problem and enhance the quality of life for hypertensive patients.</p>","PeriodicalId":7427,"journal":{"name":"American journal of cardiovascular disease","volume":"14 6","pages":"396-413"},"PeriodicalIF":1.3000,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11744219/pdf/","citationCount":"0","resultStr":"{\"title\":\"Long-acting nifedipine in the management of essential hypertension: a review for cardiologists.\",\"authors\":\"Prakash Kumar Hazra, Ashwani Mehta, Bhupen Desai, Umeshwar Pandey, Kapil Dev Mehta, Sarita Bajpai, Deepak Prasad\",\"doi\":\"10.62347/RPMZ6407\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Calcium channel antagonists, specifically long-acting nifedipine formulations, play a crucial role in treating hypertension and angina. Originally used for angina, nifedipine has been widely employed as an antihypertensive medication for over 40 years. It offers rapid action and oral bioavailability with minimal maternal or fetal side effects, making it suitable for treating hypertensive crises during pregnancy. However, it can cause a sudden drop in blood pressure and tachycardia. Long-acting formulations, such as gastrointestinal therapeutic systems, gradually release nifedipine over 24 hours, mitigating these issues. This review aims to assess the clinical efficacy and safety of long-acting nifedipine formulations in managing essential hypertension, with a focus on improving blood pressure control and addressing challenges in uncontrolled and resistant hypertension. Furthermore, long-acting nifedipine provides therapeutic advantages beyond hypertension management, showing efficacy in treating comorbid conditions such as chronic kidney disease and diabetes. Global studies support its efficacy, suggesting that a shift toward the use of long-acting nifedipine can help address the global hypertension problem and enhance the quality of life for hypertensive patients.</p>\",\"PeriodicalId\":7427,\"journal\":{\"name\":\"American journal of cardiovascular disease\",\"volume\":\"14 6\",\"pages\":\"396-413\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2024-12-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11744219/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American journal of cardiovascular disease\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.62347/RPMZ6407\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of cardiovascular disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.62347/RPMZ6407","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
Long-acting nifedipine in the management of essential hypertension: a review for cardiologists.
Calcium channel antagonists, specifically long-acting nifedipine formulations, play a crucial role in treating hypertension and angina. Originally used for angina, nifedipine has been widely employed as an antihypertensive medication for over 40 years. It offers rapid action and oral bioavailability with minimal maternal or fetal side effects, making it suitable for treating hypertensive crises during pregnancy. However, it can cause a sudden drop in blood pressure and tachycardia. Long-acting formulations, such as gastrointestinal therapeutic systems, gradually release nifedipine over 24 hours, mitigating these issues. This review aims to assess the clinical efficacy and safety of long-acting nifedipine formulations in managing essential hypertension, with a focus on improving blood pressure control and addressing challenges in uncontrolled and resistant hypertension. Furthermore, long-acting nifedipine provides therapeutic advantages beyond hypertension management, showing efficacy in treating comorbid conditions such as chronic kidney disease and diabetes. Global studies support its efficacy, suggesting that a shift toward the use of long-acting nifedipine can help address the global hypertension problem and enhance the quality of life for hypertensive patients.